http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 05 Oct 2026 10:00:14 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Assembly+Bio+to+present+Phase+1a+data+for+ABI-6250+at+AASLD+2026/27146970.html <p>Assembly Biosciences, Inc. (Nasdaq: ASMB) announced it will present two posters featuring Phase 1a data from its ABI-6250 program at The Liver Meeting 2026, hosted by the American Association for the Study of Liver Diseases (AASLD) in Denver, Colorado, from November 5–9, 2026.</p> <p>The presentations will cover safety, tolerability, and pharmacodynamic findings from a randomized, blinded Phase 1a study of ABI-6250 in healthy participants. According to the company, ABI-6250 was well tolerated at evaluated doses with no serious adverse events reported. The drug demonstrated dose-dependent, reversible increases in total and conjugated bile acids, consistent with sodium taurocholate co-transporting polypeptide (NTCP) target http://www.streetinsider.com/FDA/Assembly+Bio+to+present+Phase+1a+data+for+ABI-6250+at+AASLD+2026/27146970.html Mon, 05 Oct 2026 10:00:14 -0400 ASMB http://www.streetinsider.com/Press+Releases/Assembly+Biosciences+to+Present+Positive+Phase+1a+Safety%2C+Tolerability+and+Target+Engagement+Data+for+ABI-6250+at+AASLD+The+Liver+Meeting%C2%AE+2026/27146943.html <p><strong>ABI-6250&apos;s pharmacodynamic analysis was recognized as a Poster of Distinction</strong></p><p>SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase 1a data from its ABI-6250 program will be presented at The Liver Meeting<strong>®</strong> 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-9, 2026, in Denver, Colorado.</p> <p>“The Phase 1a findings support ABI-6250’s safety profile and demonstrate potent target engagement, and we are pleased http://www.streetinsider.com/Press+Releases/Assembly+Biosciences+to+Present+Positive+Phase+1a+Safety%2C+Tolerability+and+Target+Engagement+Data+for+ABI-6250+at+AASLD+The+Liver+Meeting%C2%AE+2026/27146943.html Mon, 05 Oct 2026 10:00:00 -0400 ASMB http://www.streetinsider.com/Globe+Newswire/Assembly+Biosciences+to+Present+Positive+Phase+1a+Safety%2C+Tolerability+and+Target+Engagement+Data+for+ABI-6250+at+AASLD+The+Liver+Meeting%C2%AE+2026/27146943.html <p><strong>ABI-6250&apos;s pharmacodynamic analysis was recognized as a Poster of Distinction</strong></p><p>SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase 1a data from its ABI-6250 program will be presented at The Liver Meeting<strong>®</strong> 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-9, 2026, in Denver, Colorado.</p> <p>“The Phase 1a findings support ABI-6250’s safety profile and demonstrate potent target engagement, and we are pleased http://www.streetinsider.com/Globe+Newswire/Assembly+Biosciences+to+Present+Positive+Phase+1a+Safety%2C+Tolerability+and+Target+Engagement+Data+for+ABI-6250+at+AASLD+The+Liver+Meeting%C2%AE+2026/27146943.html Mon, 05 Oct 2026 10:00:00 -0400 ASMB http://www.streetinsider.com/Press+Releases/Assembly+Biosciences+to+Present+at+the+H.C.+Wainwright+%26amp%3B+Co.+28th+Annual+Global+Investment+Conference/27048594.html <p>SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright &amp; Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.</p> <p>A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be accessible following the event. To register for the live webcast and replay, please visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=N1kb-WKAqR4pw0PfRHxg5cQCJopYiTSq19d14U7cSirdVfN1HRu4hybIW2iIl8zgSO7-PkwmTzEErqaEwhjl9_iM6MGP6v09Mt9W2AvVc86VzurA_aB5iQ_jJtQTaEuXf9Ct5n_62hRhTeX02hHcznFU_4wb-NaofmnDK0U3OrM9Y1CMdvw5vTyaCJoiaDw1" rel="nofollow" target="_blank">https://investor.assemblybio.com/events-presentations</a>.</p> <p><strong>About Assembly Biosciences</strong> http://www.streetinsider.com/Press+Releases/Assembly+Biosciences+to+Present+at+the+H.C.+Wainwright+%26amp%3B+Co.+28th+Annual+Global+Investment+Conference/27048594.html Thu, 10 Sep 2026 16:15:00 -0400 ASMB http://www.streetinsider.com/Globe+Newswire/Assembly+Biosciences+to+Present+at+the+H.C.+Wainwright+%26amp%3B+Co.+28th+Annual+Global+Investment+Conference/27048594.html <p>SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright &amp; Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.</p> <p>A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be accessible following the event. To register for the live webcast and replay, please visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=N1kb-WKAqR4pw0PfRHxg5cQCJopYiTSq19d14U7cSirdVfN1HRu4hybIW2iIl8zgSO7-PkwmTzEErqaEwhjl9_iM6MGP6v09Mt9W2AvVc86VzurA_aB5iQ_jJtQTaEuXf9Ct5n_62hRhTeX02hHcznFU_4wb-NaofmnDK0U3OrM9Y1CMdvw5vTyaCJoiaDw1" rel="nofollow" target="_blank">https://investor.assemblybio.com/events-presentations</a>.</p> <p><strong>About Assembly Biosciences</strong> http://www.streetinsider.com/Globe+Newswire/Assembly+Biosciences+to+Present+at+the+H.C.+Wainwright+%26amp%3B+Co.+28th+Annual+Global+Investment+Conference/27048594.html Thu, 10 Sep 2026 16:15:00 -0400 ASMB http://www.streetinsider.com/Press+Releases/Assembly+Biosciences+to+Present+at+the+H.C.+Wainwright+%26+Co.+28th+Annual+Global+Investment+Conference/27048568.html <p>SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright &amp; Co. 28^th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.</p> <p>A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be accessible following the event. To register for the live webcast and replay, please visit: <a href="https://www.globenewswire.com/Tracker?data=N1kb-WKAqR4pw0PfRHxg5cQCJopYiTSq19d14U7cSirdVfN1HRu4hybIW2iIl8zgSO7-PkwmTzEErqaEwhjl9_iM6MGP6v09Mt9W2AvVc86VzurA_aB5iQ_jJtQTaEuXf9Ct5n_62hRhTeX02hHcznFU_4wb-NaofmnDK0U3OrM9Y1CMdvw5vTyaCJoiaDw1" rel="nofollow" target="_blank">https://investor.assemblybio.com/events-presentations</a>.</p> <p><strong>About Assembly Biosciences</strong> <br http://www.streetinsider.com/Press+Releases/Assembly+Biosciences+to+Present+at+the+H.C.+Wainwright+%26+Co.+28th+Annual+Global+Investment+Conference/27048568.html Thu, 10 Sep 2026 16:15:00 -0400 ASMB http://www.streetinsider.com/Globe+Newswire/Assembly+Biosciences+to+Present+at+the+H.C.+Wainwright+%26+Co.+28th+Annual+Global+Investment+Conference/27048568.html <p>SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright &amp; Co. 28^th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.</p> <p>A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be accessible following the event. To register for the live webcast and replay, please visit: <a href="https://www.globenewswire.com/Tracker?data=N1kb-WKAqR4pw0PfRHxg5cQCJopYiTSq19d14U7cSirdVfN1HRu4hybIW2iIl8zgSO7-PkwmTzEErqaEwhjl9_iM6MGP6v09Mt9W2AvVc86VzurA_aB5iQ_jJtQTaEuXf9Ct5n_62hRhTeX02hHcznFU_4wb-NaofmnDK0U3OrM9Y1CMdvw5vTyaCJoiaDw1" rel="nofollow" target="_blank">https://investor.assemblybio.com/events-presentations</a>.</p> <p><strong>About Assembly Biosciences</strong> <br http://www.streetinsider.com/Globe+Newswire/Assembly+Biosciences+to+Present+at+the+H.C.+Wainwright+%26+Co.+28th+Annual+Global+Investment+Conference/27048568.html Thu, 10 Sep 2026 16:15:00 -0400 ASMB http://www.streetinsider.com/Corporate+News/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html <p>Assembly Biosciences, Inc. (Nasdaq: ASMB) announced it has exercised its option to share 40% of U.S. development costs and profits for its herpes simplex virus (HSV) helicase-primase inhibitor (HPI) program under its collaboration agreement with Gilead Sciences, Inc.</p><p>The program targets recurrent genital herpes and includes two investigational compounds, GS-1179 and GS-5366. Gilead retains sole responsibility for clinical development and commercialization of the program.</p><p>Under the collaboration terms, Assembly Bio is eligible to receive up to $280 million in regulatory and commercial milestones, plus tiered royalties on net sales outside the U.S. ranging from the high single digits to low teens. If http://www.streetinsider.com/Corporate+News/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html Tue, 08 Sep 2026 16:00:38 -0400 ASMB GILD http://www.streetinsider.com/FDA/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html <p>Assembly Biosciences, Inc. (Nasdaq: ASMB) announced it has exercised its option to share 40% of U.S. development costs and profits for its herpes simplex virus (HSV) helicase-primase inhibitor (HPI) program under its collaboration agreement with Gilead Sciences, Inc.</p><p>The program targets recurrent genital herpes and includes two investigational compounds, GS-1179 and GS-5366. Gilead retains sole responsibility for clinical development and commercialization of the program.</p><p>Under the collaboration terms, Assembly Bio is eligible to receive up to $280 million in regulatory and commercial milestones, plus tiered royalties on net sales outside the U.S. ranging from the high single digits to low teens. If http://www.streetinsider.com/FDA/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html Tue, 08 Sep 2026 16:00:38 -0400 ASMB GILD http://www.streetinsider.com/Hot+Corp.+News/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html <p>Assembly Biosciences, Inc. (Nasdaq: ASMB) announced it has exercised its option to share 40% of U.S. development costs and profits for its herpes simplex virus (HSV) helicase-primase inhibitor (HPI) program under its collaboration agreement with Gilead Sciences, Inc.</p><p>The program targets recurrent genital herpes and includes two investigational compounds, GS-1179 and GS-5366. Gilead retains sole responsibility for clinical development and commercialization of the program.</p><p>Under the collaboration terms, Assembly Bio is eligible to receive up to $280 million in regulatory and commercial milestones, plus tiered royalties on net sales outside the U.S. ranging from the high single digits to low teens. If http://www.streetinsider.com/Hot+Corp.+News/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html Tue, 08 Sep 2026 16:00:38 -0400 ASMB GILD http://www.streetinsider.com/Corporate+News/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html <p>Assembly Biosciences, Inc. (Nasdaq: ASMB) announced it has exercised its option to share 40% of U.S. development costs and profits for its herpes simplex virus (HSV) helicase-primase inhibitor (HPI) program under its collaboration agreement with Gilead Sciences, Inc.</p><p>The program targets recurrent genital herpes and includes two investigational compounds, GS-1179 and GS-5366. Gilead retains sole responsibility for clinical development and commercialization of the program.</p><p>Under the collaboration terms, Assembly Bio is eligible to receive up to $280 million in regulatory and commercial milestones, plus tiered royalties on net sales outside the U.S. ranging from the high single digits to low teens. If http://www.streetinsider.com/Corporate+News/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html Tue, 08 Sep 2026 16:00:38 -0400 ASMB GILD http://www.streetinsider.com/FDA/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html <p>Assembly Biosciences, Inc. (Nasdaq: ASMB) announced it has exercised its option to share 40% of U.S. development costs and profits for its herpes simplex virus (HSV) helicase-primase inhibitor (HPI) program under its collaboration agreement with Gilead Sciences, Inc.</p><p>The program targets recurrent genital herpes and includes two investigational compounds, GS-1179 and GS-5366. Gilead retains sole responsibility for clinical development and commercialization of the program.</p><p>Under the collaboration terms, Assembly Bio is eligible to receive up to $280 million in regulatory and commercial milestones, plus tiered royalties on net sales outside the U.S. ranging from the high single digits to low teens. If http://www.streetinsider.com/FDA/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html Tue, 08 Sep 2026 16:00:38 -0400 ASMB GILD http://www.streetinsider.com/Hot+Corp.+News/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html <p>Assembly Biosciences, Inc. (Nasdaq: ASMB) announced it has exercised its option to share 40% of U.S. development costs and profits for its herpes simplex virus (HSV) helicase-primase inhibitor (HPI) program under its collaboration agreement with Gilead Sciences, Inc.</p><p>The program targets recurrent genital herpes and includes two investigational compounds, GS-1179 and GS-5366. Gilead retains sole responsibility for clinical development and commercialization of the program.</p><p>Under the collaboration terms, Assembly Bio is eligible to receive up to $280 million in regulatory and commercial milestones, plus tiered royalties on net sales outside the U.S. ranging from the high single digits to low teens. If http://www.streetinsider.com/Hot+Corp.+News/Assembly+Bio+exercises+U.S.+profit-share+option+with+Gilead+for+herpes+program/27036464.html Tue, 08 Sep 2026 16:00:38 -0400 ASMB GILD http://www.streetinsider.com/Press+Releases/Assembly+Biosciences+Exercises+U.S.+Profit-Share+Option+with+Gilead+for+HSV+Helicase-Primase+Inhibitor+Program/27036445.html <p align="center"><em>– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –</em></p> <p align="center"><em>– Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 –</em></p> <p>SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it has exercised its option to share 40% of the development costs and profits in the United States for its herpes simplex http://www.streetinsider.com/Press+Releases/Assembly+Biosciences+Exercises+U.S.+Profit-Share+Option+with+Gilead+for+HSV+Helicase-Primase+Inhibitor+Program/27036445.html Tue, 08 Sep 2026 16:00:00 -0400 ASMB http://www.streetinsider.com/Globe+Newswire/Assembly+Biosciences+Exercises+U.S.+Profit-Share+Option+with+Gilead+for+HSV+Helicase-Primase+Inhibitor+Program/27036445.html <p align="center"><em>– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –</em></p> <p align="center"><em>– Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 –</em></p> <p>SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it has exercised its option to share 40% of the development costs and profits in the United States for its herpes simplex http://www.streetinsider.com/Globe+Newswire/Assembly+Biosciences+Exercises+U.S.+Profit-Share+Option+with+Gilead+for+HSV+Helicase-Primase+Inhibitor+Program/27036445.html Tue, 08 Sep 2026 16:00:00 -0400 ASMB http://www.streetinsider.com/New+Coverage/UBS+Starts+Assembly+Biosciences+%28ASMB%29+at+Buy/27007640.html (Updated - September 1, 2026 4:51 AM EDT) <p>UBS analyst Ashwani Verma initiates coverage on Assembly Biosciences (NASDAQ: ASMB) with a Buy rating and a price target of $52.00.</p><p>The analyst comments "We initiate coverage of Assembly Bio with a Buy rating and PT of $52/sh, reflecting what we view as a de-risked antiviral platform anchored by Gilead's development of the HSV franchise and upside from the company's wholly owned liver disease portfolio. We believe GS-1179 can address the high unmet need in recurrent genital herpes, given that the Ph2 outcome is de-risked by Ph1b data demonstrating a superior profile vs. SoC. http://www.streetinsider.com/New+Coverage/UBS+Starts+Assembly+Biosciences+%28ASMB%29+at+Buy/27007640.html Tue, 01 Sep 2026 04:51:37 -0400 ASMB http://www.streetinsider.com/Analyst+Comments/UBS+Starts+Assembly+Biosciences+%28ASMB%29+at+Buy/27007640.html (Updated - September 1, 2026 4:51 AM EDT) <p>UBS analyst Ashwani Verma initiates coverage on Assembly Biosciences (NASDAQ: ASMB) with a Buy rating and a price target of $52.00.</p><p>The analyst comments "We initiate coverage of Assembly Bio with a Buy rating and PT of $52/sh, reflecting what we view as a de-risked antiviral platform anchored by Gilead's development of the HSV franchise and upside from the company's wholly owned liver disease portfolio. We believe GS-1179 can address the high unmet need in recurrent genital herpes, given that the Ph2 outcome is de-risked by Ph1b data demonstrating a superior profile vs. SoC. http://www.streetinsider.com/Analyst+Comments/UBS+Starts+Assembly+Biosciences+%28ASMB%29+at+Buy/27007640.html Tue, 01 Sep 2026 04:51:37 -0400 ASMB http://www.streetinsider.com/Analyst+PT+Change/Assembly+Biosciences+%28ASMB%29+PT+Lowered+to+%2445+at+Mizuho/27004622.html <p>Mizuho analyst Salim Syed lowered the price target on Assembly Biosciences (NASDAQ: ASMB) to $45.00 (from $53.00) while maintaining a Outperform rating.</p><p>The analyst comments "ASMB (OP, increasing PT to $53): GS-1179 (HSV; formerly ABI-1179) selected to advance to Ph2; ASMB potential opt-in decision (40% U.S. cost/profit-share) expected by YE2026 (remains key near-term question, in our view). We increase our HSV PoS to 50% from 35% (GS-1179 moving forward); increase ABI-6250 PoS to 30% in HDV (from 20%) and to 25% in PBC/PSC (from 20%). We will pay attention to GS-1179 – Ph2 initiation and potential opt-in decision, by YE26; ABI-6250 http://www.streetinsider.com/Analyst+PT+Change/Assembly+Biosciences+%28ASMB%29+PT+Lowered+to+%2445+at+Mizuho/27004622.html Mon, 31 Aug 2026 14:00:32 -0400 ASMB http://www.streetinsider.com/Analyst+Comments/Assembly+Biosciences+%28ASMB%29+PT+Lowered+to+%2445+at+Mizuho/27004622.html <p>Mizuho analyst Salim Syed lowered the price target on Assembly Biosciences (NASDAQ: ASMB) to $45.00 (from $53.00) while maintaining a Outperform rating.</p><p>The analyst comments "ASMB (OP, increasing PT to $53): GS-1179 (HSV; formerly ABI-1179) selected to advance to Ph2; ASMB potential opt-in decision (40% U.S. cost/profit-share) expected by YE2026 (remains key near-term question, in our view). We increase our HSV PoS to 50% from 35% (GS-1179 moving forward); increase ABI-6250 PoS to 30% in HDV (from 20%) and to 25% in PBC/PSC (from 20%). We will pay attention to GS-1179 – Ph2 initiation and potential opt-in decision, by YE26; ABI-6250 http://www.streetinsider.com/Analyst+Comments/Assembly+Biosciences+%28ASMB%29+PT+Lowered+to+%2445+at+Mizuho/27004622.html Mon, 31 Aug 2026 14:00:32 -0400 ASMB http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++/26956574.html si-local-file:///var/storage/secattach/20260820/26956574.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++/26956574.html Thu, 20 Aug 2026 16:30:00 -0400 ASMB O.09748574 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++/26956574.html si-local-file:///var/storage/secattach/20260820/26956574.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++/26956574.html Thu, 20 Aug 2026 16:30:00 -0400 ASMB O.09748574 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Assembly+Biosciences+%28ASMB%29/26940271.html <p>H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $50.00 price target on Assembly Biosciences (NASDAQ: ASMB).</p><p>The analyst commented: "On August 13, Assembly Bio reported 2Q26 results alongside two developments we regard as thesis-relevant. First, Assembly expanded ABI-6250, its oral sodium taurocholate co-transporting polypeptide (NTCP) inhibitor, beyond chronic hepatitis delta virus (HDV) infection into CLD, with a Phase 2 basket trial in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) anticipated to initiate in 1Q27 and data anticipated in 1H28, alongside the HDV Phase 2 trial expected to initiate by year-end 2026 with data anticipated in 4Q27. Second, http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Assembly+Biosciences+%28ASMB%29/26940271.html Tue, 18 Aug 2026 06:41:38 -0400 ASMB http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+Paradigm+Biocapital+Advisors+LP/26931399.html si-local-file:///var/storage/secattach/20260814/26931399.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+Paradigm+Biocapital+Advisors+LP/26931399.html Fri, 14 Aug 2026 16:31:00 -0400 ASMB O.09748574 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+Paradigm+Biocapital+Advisors+LP/26931399.html si-local-file:///var/storage/secattach/20260814/26931399.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+Paradigm+Biocapital+Advisors+LP/26931399.html Fri, 14 Aug 2026 16:31:00 -0400 ASMB O.09748574 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++ASSEMBLY+BIOSCIENCES%2C+++++For%3A+Aug+13/26930251.html si-local-file:///var/storage/secattach/20260814/26930251.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++ASSEMBLY+BIOSCIENCES%2C+++++For%3A+Aug+13/26930251.html Fri, 14 Aug 2026 16:09:00 -0400 ASMB O.09748574